Valuation: EyePoint, Inc.

Market Cap 316M 273M 258M 234M 439M 30.24B 443M 3.08B 1.19B 15.34B 1.19B 1.16B 48.92B P/E 2026 *
-1x
P/E 2027 * -1.4x
Enterprise Value -7.26M -6.29M -5.94M -5.38M -10.1M -695M -10.18M -70.83M -27.29M -353M -27.25M -26.65M -1.12B EV / Sales 2026 *
-4.22x
EV / Sales 2027 * 0.06x
Free-Float
96.47%
Yield 2026 *
-
Yield 2027 * -
1 day-13.88%
1 week-20.09%
Current month-18.67%
1 month-75.19%
3 months-71.91%
6 months-72.27%
Current year-79.97%
1 week 3.64
Extreme 3.635
4.56
1 month 3.64
Extreme 3.635
6.34
Current year 3.64
Extreme 3.635
18.87
1 year 3.64
Extreme 3.635
19.11
3 years 3.64
Extreme 3.635
30.99
5 years 2.19
Extreme 2.19
30.99
10 years 2.19
Extreme 2.19
39.4
Manager TitleAgeSince
Chief Executive Officer 67 10/07/2023
Director of Finance/CFO 61 14/11/2019
Chief Tech/Sci/R&D Officer 43 04/03/2024
Director TitleAgeSince
Director/Board Member 67 10/07/2023
Chairman 77 10/09/2018
Director/Board Member 73 25/10/2018
Date Insider Type Main position Quantity % Market Cap. Importance
20/8/26 Others

Chief Financial Officer

-139,906 0.1669%
18/8/26 Buy

Director

10,600 0.0126%
10/7/26 Exercice

Chief Executive Officer

41,393 0.0494%
Change 5-day change 1-year change 3-year change Capi.($)
-13.88%-20.09%-72.58%-66.73% 366M
-0.19%-1.15%+50.40%+92.04% 1,015B
+0.33%-2.92%+50.06%+63.19% 642B
+0.49%+2.57%+20.47%+71.21% 463B
-0.22%+1.98%+36.33%+38.93% 353B
-0.07%-9.26%+15.16%+24.78% 265B
-0.31%+0.61%+2.73%+12.04% 254B
-1.53%-14.08%+35.91%+43.21% 206B
-1.60%-7.71%-20.79%-59.60% 191B
+0.49%-3.11%+27.72%+89.12% 182B
Average -1.43%-3.74%+14.54%+30.82% 357.06B
Weighted average by Cap. +0.02%-2.21%+33.25%+57.10%

Financials

2026 *2027 *
Net sales 1.72M 1.49M 1.41M 1.27M 2.39M 165M 2.41M 16.77M 6.46M 83.56M 6.45M 6.31M 266M 17.93M 15.53M 14.67M 13.3M 24.95M 1.72B 25.14M 175M 67.41M 872M 67.33M 65.84M 2.78B
Net income -344M -298M -282M -255M -479M -32.98B -483M -3.36B -1.29B -16.73B -1.29B -1.26B -53.35B -287M -248M -235M -213M -399M -27.47B -402M -2.8B -1.08B -13.93B -1.08B -1.05B -44.43B
Net Debt -323M -280M -264M -239M -449M -30.94B -453M -3.15B -1.21B -15.7B -1.21B -1.19B -50.05B -314M -272M -257M -233M -438M -30.14B -441M -3.07B -1.18B -15.29B -1.18B -1.15B -48.75B
Logo EyePoint, Inc.
EyePoint, Inc., formerly EyePoint Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational-sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with bioerodible Durasert E technology. Vorolanib features a novel multi-mechanism of action as it targets both vascular endothelial growth factor (VEGF)-mediated vascular permeability and IL-6 mediated inflammation through inhibition of all VEGF receptors and pro-inflammatory IL-6/JAK1 signaling. DURAVYU is in Phase III pivotal trials for wet age-related macular degeneration. DURAVYU is also being advanced for the treatment of diabetic macular edema (DME) with the first patient dosing in Phase III trials.
Employees
-
Date Price Change Volume
15/09/26 US$3.660 -13.88% 3,876,152
14/09/26 US$4.250 +0.47% 2,531,741
11/09/26 US$4.230 -0.47% 2,728,042
10/09/26 US$4.250 -2.07% 4,317,047
09/09/26 US$4.340 -4.82% 2,984,523
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
3.660USD
Average target price
25.91USD
Spread / Average Target
+607.90%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EYPT Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!